RU2481123C2 - Комбинация агонистов альфа 7 никотиновых рецепторов и антипсихотических средств - Google Patents

Комбинация агонистов альфа 7 никотиновых рецепторов и антипсихотических средств Download PDF

Info

Publication number
RU2481123C2
RU2481123C2 RU2010137787/15A RU2010137787A RU2481123C2 RU 2481123 C2 RU2481123 C2 RU 2481123C2 RU 2010137787/15 A RU2010137787/15 A RU 2010137787/15A RU 2010137787 A RU2010137787 A RU 2010137787A RU 2481123 C2 RU2481123 C2 RU 2481123C2
Authority
RU
Russia
Prior art keywords
disorder
psychotic
pharmaceutical combination
psychiatric
combination according
Prior art date
Application number
RU2010137787/15A
Other languages
English (en)
Russian (ru)
Other versions
RU2010137787A (ru
Inventor
Меруан Беншериф
Грегори Дж. Гатто
Терри Хаузер
Кристен Г. ДЖОРДАН
Шэрон Р. ЛЕТЧУОРТ
Original Assignee
Таргасепт, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Таргасепт, Инк. filed Critical Таргасепт, Инк.
Publication of RU2010137787A publication Critical patent/RU2010137787A/ru
Application granted granted Critical
Publication of RU2481123C2 publication Critical patent/RU2481123C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
RU2010137787/15A 2008-02-13 2009-02-13 Комбинация агонистов альфа 7 никотиновых рецепторов и антипсихотических средств RU2481123C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2828208P 2008-02-13 2008-02-13
US61/028,282 2008-02-13
PCT/US2009/034062 WO2009102962A2 (en) 2008-02-13 2009-02-13 Combination of alpha 7 nicotinic agonists and antipsychotics

Publications (2)

Publication Number Publication Date
RU2010137787A RU2010137787A (ru) 2012-03-20
RU2481123C2 true RU2481123C2 (ru) 2013-05-10

Family

ID=40902222

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2010137787/15A RU2481123C2 (ru) 2008-02-13 2009-02-13 Комбинация агонистов альфа 7 никотиновых рецепторов и антипсихотических средств

Country Status (25)

Country Link
US (1) US20110059947A1 (https=)
EP (2) EP2254598B1 (https=)
JP (1) JP2011511845A (https=)
KR (1) KR20100113163A (https=)
CN (2) CN103143023A (https=)
AU (1) AU2009214625A1 (https=)
BR (1) BRPI0907570A2 (https=)
CA (1) CA2715268A1 (https=)
CO (1) CO6290706A2 (https=)
CY (1) CY1114492T1 (https=)
DK (1) DK2254598T3 (https=)
EC (1) ECSP10010471A (https=)
ES (1) ES2430622T3 (https=)
HR (1) HRP20130749T1 (https=)
IL (1) IL207389A0 (https=)
MX (1) MX2010008875A (https=)
NZ (1) NZ587312A (https=)
PL (1) PL2254598T3 (https=)
PT (1) PT2254598E (https=)
RS (1) RS52941B (https=)
RU (1) RU2481123C2 (https=)
SG (1) SG188144A1 (https=)
SI (1) SI2254598T1 (https=)
WO (1) WO2009102962A2 (https=)
ZA (1) ZA201005999B (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8314119B2 (en) 2006-11-06 2012-11-20 Abbvie Inc. Azaadamantane derivatives and methods of use
SA08290475B1 (ar) * 2007-08-02 2013-06-22 Targacept Inc (2s، 3r)-n-(2-((3-بيردينيل)ميثيل)-1-آزا بيسيكلو[2، 2، 2]أوكت-3-يل)بنزو فيوران-2-كربوكساميد، وصور أملاحه الجديدة وطرق استخدامه
CN103180321A (zh) 2010-09-23 2013-06-26 Abbvie公司 氮杂金刚烷衍生物的一水合物
TW201242600A (en) * 2011-01-18 2012-11-01 Targacept Inc Treatment of cognitive dysfunction in schizophrenia
US9139576B2 (en) 2011-05-03 2015-09-22 Merck Sharp & Dohme Corp. Aminomethyl biaryl benzotriazole derivatives
WO2014054635A1 (ja) * 2012-10-02 2014-04-10 大日本住友製薬株式会社 イミダゾール誘導体
JP6807094B2 (ja) * 2016-04-29 2021-01-06 国立大学法人秋田大学 クロザピン又はその誘導体の血中薬剤濃度上昇リスク判定方法及び薬剤投与量判定方法
ES2769286T3 (es) 2016-12-20 2020-06-25 Lts Lohmann Therapie Systeme Ag Sistema terapéutico transdérmico que contiene asenapina
WO2018115010A1 (en) 2016-12-20 2018-06-28 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine and polysiloxane or polyisobutylene
CN108727416B (zh) * 2017-04-20 2021-03-09 北京大学 三环杂芳香体系酰胺衍生物及其制备和用途
ES2881783T3 (es) 2017-06-26 2021-11-30 Lts Lohmann Therapie Systeme Ag Sistema terapéutico transdérmico que contiene asenapina y polímero de acrílico y silicona
CN107469087A (zh) * 2017-09-10 2017-12-15 孙永丽 用于治疗精神病的制剂
CA3101420A1 (en) 2018-06-20 2019-12-26 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine
CN112533593A (zh) 2018-06-20 2021-03-19 罗曼治疗系统股份公司 含有阿塞那平的透皮治疗系统
JP2024502470A (ja) * 2021-01-08 2024-01-19 アイエフエム デュー インコーポレイテッド Ｓｔｉｎｇ活性に関連する状態を治療するための化合物および組成物
TW202235073A (zh) 2021-01-08 2022-09-16 美商Ｉｆｍ Ｄｕｅ有限公司 用於治療與sting活性相關的病狀之化合物及組合物
DE102022114269A1 (de) 2022-06-07 2023-12-07 Rational Aktiengesellschaft Gargerät mit einem Selbstreinigungssystem sowie ein Verfahren zum Ändern von Reinigungsparametern für das Gargerät

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003070731A2 (en) * 2002-02-19 2003-08-28 Pharmacia & Upjohn Company Azabicyclic compounds for the treatment of disease
US20040002513A1 (en) * 1998-12-11 2004-01-01 Mazurov Anatoly A. 3-Substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof
WO2004052894A1 (en) * 2002-12-06 2004-06-24 Pharmacia & Upjohn Company Llc Crystalline fumarate salts of 1-azabicyclo[2.2.2]oct substituted furo[2,3-c]pyridinyl carboxamide and compositions and preparations thereof
EA005002B1 (ru) * 1999-12-10 2004-10-28 Уайт НОВЫЕ ТЕРАПЕВТИЧЕСКИЕ КОМБИНАЦИИ (S)-2-(БЕНЗИЛАМИНОМЕТИЛ)-2,3,8,9-ТЕТРАГИДРО-7H-1,4-ДИОКСИН [2,3-e]ИНДОЛ-8-ОНА И НЕЙРОЛЕПТИКОВ ДЛЯ ЛЕЧЕНИЯ ИЛИ ПРЕДОТВРАЩЕНИЯ ПСИХОТИЧЕСКИХ РАССТРОЙСТВ
WO2004099202A1 (en) * 2003-05-05 2004-11-18 Pharmacia & Upjohn Company Llc Quinuclidines substituted bentodioxine carboxamides for the treatment of neurodegenerative diseases
US20050225040A1 (en) * 2000-10-27 2005-10-13 Gerold Goertzen Obstacle traversing wheelchair
US7309699B2 (en) * 2003-12-22 2007-12-18 Abbott Laboratories 3-Quinuclidinyl amino-substituted biaryl derivatives
RU2367440C2 (ru) * 2003-04-02 2009-09-20 Новартис Аг Применение производных 10-гидрокси-10,11-дигидрокарбамазепина для лечения аффективных расстройств

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5597919A (en) * 1995-01-06 1997-01-28 Dull; Gary M. Pyrimidinyl or Pyridinyl alkenyl amine compounds
US5712270A (en) 1995-11-06 1998-01-27 American Home Products Corporation 2-arylamidothiazole derivatives with CNS activity
US5616716A (en) 1996-01-06 1997-04-01 Dull; Gary M. (3-(5-ethoxypyridin)yl)-alkenyl 1 amine compounds
SE9600683D0 (sv) 1996-02-23 1996-02-23 Astra Ab Azabicyclic esters of carbamic acids useful in therapy
US5663356A (en) 1996-04-23 1997-09-02 Ruecroft; Graham Method for preparation of aryl substituted alefinic secondary amino compounds
AR013184A1 (es) 1997-07-18 2000-12-13 Astrazeneca Ab Aminas heterociclicas espiroazobiciclicas, composicion farmaceutica, uso de dichas aminas para preparar medicamentos y metodo de tratamiento o profilaxis
EP1083889B1 (en) 1998-06-01 2003-12-10 Ortho-McNeil Pharmaceutical, Inc. Tetrahydronaphtalene compounds and their use for the treatment of neurodegenerative diseases
SE9904176D0 (sv) 1999-11-18 1999-11-18 Astra Ab New use
CZ294251B6 (cs) * 2000-06-27 2004-11-10 Laboratorios S. A. L. V. A. T., S. A. Karbamáty a jejich použití pro výrobu farmaceutického prostředku
US6479510B2 (en) 2000-08-18 2002-11-12 Pharmacia & Upjohn Company Quinuclidine-substituted aryl compounds for treatment of disease
US6492386B2 (en) 2000-08-18 2002-12-10 Pharmacia & Upjohn Company Quinuclidine-substituted aryl compounds for treatment of disease
US6486172B2 (en) 2000-08-18 2002-11-26 Pharmacia & Upjohn Company Quinuclidine-substituted aryl compounds for treatment of disease
US6599916B2 (en) 2000-08-21 2003-07-29 Pharmacia & Upjohn Company Quinuclidine-substituted heteroaryl moieties for treatment of disease
WO2002017358A2 (en) 2000-08-21 2002-02-28 Pharmacia & Upjohn Company Quinuclidine-substituted heteroaryl moieties for treatment of disease (nicotinic acetylcholine receptor antagonists)
EP1311505A2 (en) 2000-08-21 2003-05-21 PHARMACIA & UPJOHN COMPANY Quinuclidine-substituted heteroaryl moieties for treatment of disease ( nicotinic acetylcholine receptor ligands )
JP4445704B2 (ja) 2000-12-22 2010-04-07 アルミラル・ソシエダッド・アノニマ キヌクリジンカルバメート誘導体およびｍ３アンダゴニストとしてのそれらの使用
WO2005063296A2 (en) * 2003-12-23 2005-07-14 Pfizer Products Inc. Therapeutic combination for cognition enhancement and psychotic disorders
EP1863485A2 (en) * 2005-03-18 2007-12-12 Abbott Laboratories Alpha7 neuronal nicotinic receptor ligand and antipsychotic compositions

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040002513A1 (en) * 1998-12-11 2004-01-01 Mazurov Anatoly A. 3-Substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof
US6953855B2 (en) * 1998-12-11 2005-10-11 Targacept, Inc. 3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof
EA005002B1 (ru) * 1999-12-10 2004-10-28 Уайт НОВЫЕ ТЕРАПЕВТИЧЕСКИЕ КОМБИНАЦИИ (S)-2-(БЕНЗИЛАМИНОМЕТИЛ)-2,3,8,9-ТЕТРАГИДРО-7H-1,4-ДИОКСИН [2,3-e]ИНДОЛ-8-ОНА И НЕЙРОЛЕПТИКОВ ДЛЯ ЛЕЧЕНИЯ ИЛИ ПРЕДОТВРАЩЕНИЯ ПСИХОТИЧЕСКИХ РАССТРОЙСТВ
US20050225040A1 (en) * 2000-10-27 2005-10-13 Gerold Goertzen Obstacle traversing wheelchair
WO2003070731A2 (en) * 2002-02-19 2003-08-28 Pharmacia & Upjohn Company Azabicyclic compounds for the treatment of disease
WO2004052894A1 (en) * 2002-12-06 2004-06-24 Pharmacia & Upjohn Company Llc Crystalline fumarate salts of 1-azabicyclo[2.2.2]oct substituted furo[2,3-c]pyridinyl carboxamide and compositions and preparations thereof
RU2367440C2 (ru) * 2003-04-02 2009-09-20 Новартис Аг Применение производных 10-гидрокси-10,11-дигидрокарбамазепина для лечения аффективных расстройств
WO2004099202A1 (en) * 2003-05-05 2004-11-18 Pharmacia & Upjohn Company Llc Quinuclidines substituted bentodioxine carboxamides for the treatment of neurodegenerative diseases
US7309699B2 (en) * 2003-12-22 2007-12-18 Abbott Laboratories 3-Quinuclidinyl amino-substituted biaryl derivatives

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ЭНЦИКЛОПЕДИЧЕСКИЙ СЛОВАРЬ МЕДИЦИНСКИХ ТЕРМИНОВ. - М.: Медицина, 2001, с.742, статья «синергизм». *

Also Published As

Publication number Publication date
MX2010008875A (es) 2010-08-31
PL2254598T3 (pl) 2013-12-31
WO2009102962A2 (en) 2009-08-20
RS52941B (sr) 2014-02-28
RU2010137787A (ru) 2012-03-20
EP2254598A2 (en) 2010-12-01
ES2430622T3 (es) 2013-11-21
CA2715268A1 (en) 2009-08-20
HRP20130749T1 (en) 2013-10-11
CO6290706A2 (es) 2011-06-20
SG188144A1 (en) 2013-03-28
BRPI0907570A2 (pt) 2019-09-24
JP2011511845A (ja) 2011-04-14
IL207389A0 (en) 2010-12-30
CN103143023A (zh) 2013-06-12
US20110059947A1 (en) 2011-03-10
WO2009102962A3 (en) 2009-10-08
HK1147954A1 (en) 2011-08-26
ZA201005999B (en) 2011-05-25
EP2633868A1 (en) 2013-09-04
CY1114492T1 (el) 2016-10-05
NZ587312A (en) 2011-12-22
CN101977628A (zh) 2011-02-16
AU2009214625A1 (en) 2009-08-20
DK2254598T3 (da) 2013-07-29
PT2254598E (pt) 2013-10-16
KR20100113163A (ko) 2010-10-20
SI2254598T1 (sl) 2013-10-30
ECSP10010471A (es) 2010-10-30
EP2254598B1 (en) 2013-07-10

Similar Documents

Publication Publication Date Title
RU2481123C2 (ru) Комбинация агонистов альфа 7 никотиновых рецепторов и антипсихотических средств
JP6668387B2 (ja) 薬物の投与及び混合のための装置及び方法、並びにそのための適切な技法のトレーニング
ES2668380T3 (es) Moduladores de receptores de andrógenos y sus usos
HRP20200575T1 (hr) Spojevi karbamata i postupci pripremanja i korištenja istih
US10300054B2 (en) Methods for treating antipsychotic-induced weight gain
JP2016512558A5 (https=)
JP2017505316A5 (https=)
JP2015537003A5 (https=)
HRP20100434T1 (hr) Postupci liječenja zaraze virusom hiv
US20050171086A1 (en) Compositions for treating CNS disorders
SI2889033T1 (en) Treatment of negative symptoms of schizophrenia with (R) -7-chloro-N- (chonylidin-3-yl) benzo (B) thiophene-2-carboxamide and pharmaceutically acceptable salts thereof
CN104546852A (zh) 用于治疗精神分裂症的(硫代)-氨甲酰基-环己烷衍生物和方法
CY1113670T1 (el) Φαρμακευτικη συνθεση για τη θεραπεια της υπερδραστηριας ουροδοχου κυστης
PE20191240A1 (es) Formas de administracion farmaceutica que contienen inhibidores de canales task-1 y task-3 y su uso para el tratamiento de trastornos respiratorios
JP2008533142A (ja) α７ニューロンニコチン性受容体リガンドおよび抗精神病薬組成物
EP2012784A1 (en) Mono and combination therapy of m1/m4 agonist (sabcomeline) for treatment of negative symptoms of schizophrenia
KR101867633B1 (ko) 정신분열증을 치료하기 위한 시클릭 아미드 유도체의 사용 방법
Bergemann et al. Estrogen in the treatment of late-onset schizophrenia
WO2005065372A3 (en) Methods and compositions using thalidomide for the treatment and management of central nervous system disorders or diseases
HRP20170773T1 (hr) Novi anti-malarijski agensi
Rodriguez-Cabezas et al. Priapism associated with iloperidone: a case report
WO2009073146A3 (en) Use of immunomodulatory compounds for the treatment of transverse myelitis, multiple sclerosis, and other disorders
Teng et al. Paliperidone-related rabbit syndrome
ES3015458T3 (en) Blend containing aripiprazole and a carbamate compound for prevention, mitigation, or treatment of schizophrenia
Nyilas et al. 36–Long-term efficacy and safety of aripiprazole in pediatric patients with bipolar I disorder

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20150214